RT Journal Article
SR Electronic
T1 Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3741
OP 3746
DO 10.21873/anticanres.15165
VO 41
IS 8
A1 ANIE PRISCILLA MASILAMANI
A1 ALEXANDRA FISCHER
A1 SUSANNE SCHULTZE-SEEMANN
A1 IRINA KUCKUCK
A1 ISIS WOLF
A1 FRANZ FRIEDRICH DRESSLER
A1 CHRISTIAN GRATZKE
A1 PHILIPP WOLF
YR 2021
UL http://ar.iiarjournals.org/content/41/8/3741.abstract
AB Background/Aim: Reports on over-expression of the epidermal growth factor receptor (EGFR) in bladder cancer and its function in tumorigenesis have suggested to target this antigen. Materials and Methods: We generated the targeted toxin EGF-PE40 consisting of the human epidermal growth factor (EGF) as the binding domain and PE40, a truncated version of Pseudomonas Exotoxin A, as the toxin domain. EGF-PE40 was tested on EGFR-expressing bladder cancer cells in view of binding via flow cytometry, and cytotoxicity via WST viability assay. Induction of apoptosis was examined by western blot. Results: The targeted toxin specifically triggered cytotoxicity in the bladder cancer cells with 50% inhibitory concentration (IC50) values in the low nanomolar or picomolar range, and was about 1,250- to 1,500-fold more cytotoxic than the EGFR inhibitor erlotinib. Cytotoxicity of EGF-PE40 was based on the induction of apoptosis. Conclusion: EGF-PE40 represents a promising candidate for the future treatment of bladder cancer.